Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
US9861705B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9861705-B2 |
| Application number | US-201113884901-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 11, 2011 |
| Priority date | Nov 12, 2010 |
| Publication date | Jan 9, 2018 |
| Grant date | Jan 9, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
Opening claim text (preview).
What is claimed is: 1. A conjugate of an interleukin-2 (IL-2) moiety having the amino acid sequence of SEQ ID NO: 3, the conjugate comprising one to seven water-soluble polymers covalently attached via a releasable linkage to amino groups within the IL-2 moiety, wherein any given amino group within the IL-2 moiety has at most one water-soluble polymer covalently attached via the releasable linkage thereto, and further wherein: (i) each water-soluble polymer has a weight-average molecular weight in the range of from about 20,000 Daltons to about 85,000 Daltons; and (ii) at least one water-soluble polymer is releasably covalently attached at an amino group of a lysine within the IL-2 moiety. 2. The conjugate of claim 1 , wherein the water-soluble polymer is a branched water-soluble polymer. 3. The conjugate of claim 2 , wherein the branched water-soluble polymer is a branched poly(ethylene glycol). 4. The conjugate of claim 3 , wherein each branched poly(ethylene glycol) has a weight-average molecular weight of about 20,000 Daltons. 5. The conjugate of claim 4 , wherein each branched poly(ethylene glycol) comprises two poly(ethylene glycol) chains. 6. The conjugate of claim 1 , wherein the water-soluble polymer is a polymer selected from the group consisting of poly(alkylene oxide), poly(vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, and poly(acryloylmorpholine). 7. The conjugate of claim 6 , wherein the water-soluble polymer is a poly(alkylene oxide). 8. The conjugate of claim 7 , wherein the poly(alkylene oxide) is a poly(ethylene glycol). 9. The conjugate of claim 8 , wherein the poly(ethylene glycol) is terminally capped with an end-capping moiety selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy, substituted alkynoxy, aryloxy and substituted aryloxy. 10. The conjugate of claim 1 , wherein one, two, three or four water-soluble polymers are attached to the residue of the IL-2 moiety. 11. The conjugate of claim 1 , wherein one, two or three water-soluble polymers are attached to the IL-2 moiety. 12. The conjugate of claim 1 , wherein one or two water-soluble polymers are attached to the IL-2 moiety. 13. The conjugate of claim 1 , wherein one water-soluble polymer is attached to the IL-2 moiety. 14. A composition comprising a plurality of conjugates according to claim 8 . 15. The composition of claim 14 , wherein the plurality of conjugates is a mixture of monoPEGylated, diPEGYlated and triPEGylated conjugates. 16. The composition of claim 14 , wherein the plurality of conjugates has four or more poly(ethylene glycol) polymers covalently attached to the IL-2 moiety. 17. A pharmaceutical composition comprising a conjugate of claim 1 and a pharmaceutically acceptable excipient. 18. A method comprising administering to an individual a pharmaceutical composition of claim 17 .
Related publications grouped by family.
Answers are generated from the same data shown on this page.